{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.1","value":"184"},{"groupId":"OG001","spread":"66.1","value":"83.1"},{"groupId":"OG002","spread":"64.7","value":"187"},{"groupId":"OG003","spread":"56.6","value":"85.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"78"}],"units":"Participants"}],"title":"Decitabine: Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"54.7","value":"145"},{"groupId":"OG003","spread":"58.5","value":"139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"76"}],"units":"Participants"}],"title":"Decitabine: Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.2","value":"180"},{"groupId":"OG001","spread":"62.8","value":"140"},{"groupId":"OG002","spread":"62.4","value":"192"},{"groupId":"OG003","spread":"62.7","value":"139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"76"}],"units":"Participants"}],"title":"Decitabine: Day 5"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"53.8","value":"321"},{"groupId":"OG003","spread":"47.7","value":"313"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"78"}],"units":"Participants"}],"title":"Cedazuridine: Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"49.1","value":"349"},{"groupId":"OG003","spread":"43.4","value":"343"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"78"}],"units":"Participants"}],"title":"Cedazuridine: Day 2"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"51.8","value":"371"},{"groupId":"OG003","spread":"42.7","value":"350"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"77"}],"units":"Participants"}],"title":"Cedazuridine: Day 5"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"65.7","value":"150"},{"groupId":"OG003","spread":"60.0","value":"182"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"79"}],"units":"Participants"}],"title":"Cedazuridine-epimer: Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"64.6","value":"155"},{"groupId":"OG003","spread":"59.2","value":"204"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"78"}],"units":"Participants"}],"title":"Cedazuridine-epimer: Day 2"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"65.9","value":"169"},{"groupId":"OG003","spread":"58.4","value":"191"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"77"}],"units":"Participants"}],"title":"Cedazuridine-epimer: Day 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"79"}],"units":"Participants"}],"description":"Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with MDS or CMML received decitabine 20 mg/m\\^2 IV injection, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days).","id":"OG000","title":"MDS or CMML: IV Decitabine"},{"description":"Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG001","title":"MDS or CMML: ASTX727"},{"description":"Participants with AML received decitabine 20 mg/m\\^2 IV injection, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days).","id":"OG002","title":"AML: IV Decitabine"},{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, given by mouth, once daily, on Days 1 to 5 in cycle 1 or 2 (each cycle = 28 days). From cycle 3, participants received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG003","title":"AML: ASTX727"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Overall PK Analysis Set included participants not included in Primary Endpoint PK Analysis Set, received any amount of study treatment, complied with protocol sufficiently to ensure PK samples were collected, provided sufficient samples to measure available plasma concentrations for decitabine. Overall number of participants analyzed:Number of participants evaluable for this outcome measure. Number analyzed:Number of participants evaluable for this outcome measure at specified time point.","reportingStatus":"POSTED","timeFrame":"ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)","title":"Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}